BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Hannah Valantine Sells 4,292 Shares of Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Hannah Valantine sold 4,292 shares of BridgeBio Pharma stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $40.00, for a total transaction of $171,680.00. Following the completion of the transaction, the director now directly owns 1,764 shares in the company, valued at $70,560. This represents a 70.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

BridgeBio Pharma Price Performance

Shares of BBIO stock opened at $39.05 on Thursday. BridgeBio Pharma, Inc. has a one year low of $21.62 and a one year high of $40.40. The stock has a fifty day moving average price of $34.92 and a 200 day moving average price of $32.91. The stock has a market cap of $7.41 billion, a P/E ratio of -13.70 and a beta of 1.10.

BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings data on Tuesday, April 29th. The company reported ($0.88) EPS for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.12. The business had revenue of $36.74 million for the quarter, compared to the consensus estimate of $57.14 million. During the same period in the previous year, the business posted ($0.20) earnings per share. BridgeBio Pharma’s revenue was down 44.8% on a year-over-year basis. Equities research analysts anticipate that BridgeBio Pharma, Inc. will post -3.67 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on BBIO. JPMorgan Chase & Co. increased their price objective on BridgeBio Pharma from $44.00 to $50.00 and gave the company an “overweight” rating in a research report on Monday, March 24th. Scotiabank upped their target price on BridgeBio Pharma from $52.00 to $55.00 and gave the company a “sector outperform” rating in a report on Wednesday, April 30th. Citigroup increased their price target on BridgeBio Pharma from $45.00 to $49.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Cantor Fitzgerald reissued an “overweight” rating and issued a $95.00 price target on shares of BridgeBio Pharma in a research note on Friday, February 21st. Finally, Piper Sandler upped their price objective on shares of BridgeBio Pharma from $46.00 to $63.00 and gave the company an “overweight” rating in a research note on Wednesday, April 30th. Two equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, BridgeBio Pharma has a consensus rating of “Moderate Buy” and a consensus target price of $57.36.

Institutional Investors Weigh In On BridgeBio Pharma

A number of institutional investors have recently added to or reduced their stakes in BBIO. Vanguard Group Inc. raised its holdings in shares of BridgeBio Pharma by 6.2% in the 4th quarter. Vanguard Group Inc. now owns 15,077,915 shares of the company’s stock worth $413,738,000 after buying an additional 879,059 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of BridgeBio Pharma by 1.9% in the 4th quarter. Janus Henderson Group PLC now owns 4,907,533 shares of the company’s stock worth $134,672,000 after purchasing an additional 89,521 shares during the last quarter. Farallon Capital Management LLC grew its holdings in shares of BridgeBio Pharma by 140.1% in the 4th quarter. Farallon Capital Management LLC now owns 4,195,000 shares of the company’s stock worth $115,111,000 after purchasing an additional 2,448,000 shares during the last quarter. Frazier Life Sciences Management L.P. increased its position in shares of BridgeBio Pharma by 1.1% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 3,800,457 shares of the company’s stock worth $104,285,000 after purchasing an additional 40,000 shares in the last quarter. Finally, Capital Research Global Investors lifted its holdings in BridgeBio Pharma by 34.9% during the 4th quarter. Capital Research Global Investors now owns 3,526,747 shares of the company’s stock valued at $96,774,000 after purchasing an additional 912,439 shares during the last quarter. 99.85% of the stock is owned by institutional investors and hedge funds.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.